http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018208122-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8c10b416bddc5935f893aa74692587e7 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-93 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y601-0101 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N1-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5091 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57492 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57407 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-573 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate | 2018-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c2c0a8d8ce9c93412432c654ed069b3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a7a1588b2a8723243fa18372bb06e5d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d19b2a76c071cc562ff4c07d59b490da http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d03a96cd0de70cf46f3a0a00e39e9c17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f17d46acb60f3411ac6259b8ba729c7e |
| publicationDate | 2018-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2018208122-A1 |
| titleOfInvention | Method for diagnosis of bile duct cancer using methionyl-trna synthetase in bile duct cell |
| abstract | The present invention relates to a method for diagnosis of bile duct cancer, using methionyl-tRNA synthetase (MRS) in bile duct cells and, more particularly, to a composition for diagnosing bile duct cancer, comprising an agent with which an expression level of methionyl-tRNA synthetase protein is measured, a diagnostic kit, and a method for qualitative or quantitative analysis of MRS to provide information necessary for the diagnosis of bile duct cancer. According to the present invention, MRS retains a very high value as a diagnostic marker for bile duct cancer in terms of rapidity and accuracy because MRS allows determination to be made to see whether bile duct cancer is present or absent for bile duct cells, which have been classified as atypical cells by conventional pathological examination methods. Hence, the present invention provides a method for discriminating between cancer cells and normal cells in atypical cells and can make a definite diagnosis of cancer with almost 100 % in all of sensitivity, specificity, and accuracy in contrast to many conventional cancer markers with which an actual result of diagnosis is substantially difficult to obtain at a cell level (that is, cytodiagnosis). |
| priorityDate | 2017-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1134.